Market Alert: Strong Nuclear Tensions in South Asia Assessing the Fallout on Global Equity Markets
Pacific Edge Limited (NZX: PEB) has encountered a major hurdle in the United States following the draft Local Coverage Determination (LCD) issued by Novitas, its Medicare administrative contractor. The LCD states that Pacific Edge's flagship product, Cxbladder, a diagnostic test for bladder cancer, is "not reasonable and necessary" for supporting effective patient outcomes and is therefore not eligible for Medicare reimbursement. This decision significantly challenges Pacific Edge’s prospects in the US market, as coverage for its primary product remains uncertain.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 28, 2025
Apr 28, 2025
Apr 24, 2025
Apr 24, 2025
Apr 23, 2025
Apr 14, 2025
Apr 11, 2025
Apr 11, 2025
Apr 10, 2025
Apr 10, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is based in Australia. The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
